601089.SHG Beijing Winsunny Pharmaceutical CO.LTD
- Market cap
- CNY 7.58B
- P/E
- 19.5x
- P/B
- 1.97x
- ROE
- 9.6%
- Dividend yield
- 3.09%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 601089.SHG undervalued?
Graham number601089.SHG trades 30.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Winsunny Pharmaceutical CO.LTD fundamental analysis
No fundamental analysis for Beijing Winsunny Pharmaceutical CO.LTD yet.
Beijing Winsunny Pharmaceutical CO.LTD stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Winsunny Pharmaceutical CO.LTD
Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical formulation and medical devices China. The company offers chemical drugs; traditional Chinese medicine; raw materials; and medical devices, such as negative pressure drainage device, digital urine collection bags, dynamic urine output monitor, disposable pressure sensor, urodynamic monitoring device, nasal air filter, medical micro-mesh nebulizer, disposable atomizer,…
Full company profileBeijing Winsunny Pharmaceutical CO.LTD financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Winsunny Pharmaceutical CO.LTD annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 2.54B | 2.84B | 3.24B | 3.34B | 3.45B | 3.50B | 3.50B |
| Gross Profit | 1.80B | 1.97B | 2.21B | 2.23B | 2.31B | 2.30B | 2.10B |
| Operating Income | 322M | 369M | 458M | 510M | 508M | 524M | 382M |
| EBITDA | - | - | 574M | 652M | 646M | 654M | 394M |
| Net Income | 263M | 314M | 439M | 489M | 489M | 469M | 365M |
| EPS | 0.73 | 0.87 | 0.91 | 1.02 | 1.02 | 0.98 | 0.76 |
| Balance Sheet | |||||||
| Total Assets | 1.72B | 2.15B | 4.32B | 4.55B | 4.82B | 4.92B | 4.95B |
| Total Liabilities | 709M | 938M | 1.14B | 1.07B | 1.26B | 1.13B | 1.11B |
| Shareholders' Equity | 1.01B | 1.21B | 3.17B | 3.47B | 3.54B | 3.78B | 3.82B |
| Cash & Short-term Investments | 270M | 435M | 2.54B | 2.53B | 794M | 634M | 552M |
| Cash Flow | |||||||
| Operating Cash Flow | 387M | 528M | 660M | 556M | 691M | 361M | - |
| Capital Expenditure | 169M | 193M | 135M | 366M | 392M | 397M | 91.0M |
| Free Cash Flow | 218M | 335M | 524M | 190M | 299M | -36.6M | 410M |
| Ratios | |||||||
| ROE | 26.1% | 26.0% | 13.8% | 14.1% | 13.8% | 12.4% | 9.6% |
| ROA | 15.3% | 14.6% | 10.2% | 10.7% | 10.1% | 9.5% | 7.4% |
| Net Profit Margin | 10.4% | 11.1% | 13.5% | 14.6% | 14.2% | 13.4% | 10.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Beijing Winsunny Pharmaceutical CO.LTD dividends
- Dividend yield
- 3.09%
- Forward dividend
- 0.50 CNY
- Payout ratio
- 49.9%
- Ex-dividend date
- Jun 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 234M | 0.49 | 49.9% |
| 2024 | CNY 237M | 0.49 | 48.4% |
| 2023 | CNY 195M | 0.41 | 39.8% |
| 2022 | CNY 111M | 0.23 | 25.3% |
| 2021 | CNY 114M | 0.32 | 36.3% |
| 2020 | CNY 119M | 0.33 | 45.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Beijing Winsunny Pharmaceutical CO.LTD
- Insiders 73.81%
- Institutions 3.99%
- Public & others 22.21%
- Shares outstanding 480M
- Free float 117M
Beijing Winsunny Pharmaceutical CO.LTD company profile
- Company name
- Beijing Winsunny Pharmaceutical CO.LTD
- Ticker
- 601089.SHG
- ISIN
- CNE100005QF9
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3,908
- Fiscal year end
- December
- Address
- No. 8, Guangyuan East Street, Beijing, China, 101113
- Phone
- 86 10 6010 0299
- Website
- foyou.com.cn
About Beijing Winsunny Pharmaceutical CO.LTD
Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical formulation and medical devices China. The company offers chemical drugs; traditional Chinese medicine; raw materials; and medical devices, such as negative pressure drainage device, digital urine collection bags, dynamic urine output monitor, disposable pressure sensor, urodynamic monitoring device, nasal air filter, medical micro-mesh nebulizer, disposable atomizer, disposable oxygen mask, and disposable oxygen tubing. It sells its products through medical institutions and retail outlets. The company's products cover cardiovascular system, chronic kidney disease, dermatology, digestive system, diabetes, neuropsychiatric system, and gynecology areas. Beijing Foyou Pharma CO.,LTD was incorporated in 1999 and is headquartered in Beijing, China.
Beijing Winsunny Pharmaceutical CO.LTD management
5- Mr. He HuangChairman & GM · born 1968
- Ms. Xu Yan YangFinancial Manager · born 1980
- Mr. Yong LiDeputy General Manager · born 1980
- Mr. Yuxian GengDeputy General Manager · born 1974
- Yan LiAccounting Supervisor